It is currently Tue Jun 28, 2016 8:22 am

News News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Neurovax presentation

Here is a link to a presentation on the Immune Response Corp's website about their clinical pipeline, including Neurovax. Not sure if there's anything new here, but it was nice to see their timeline for the upcoming phase IIb Neurovax trial.

http://www.imnr.com/ir/2006APR19.htm

if that doesn't work, this one might (select the link at the end of the first paragraph):

http://www.imnr.com/news/2006/2006APR20.htm
Read more : Neurovax presentation | Views : 1772 | Replies : 0


Transition Therapeutics

Dignan,

I stumbled across Transition Therapeutics (Canadian company). They have the following drug/s? in trial. Not sure if it / they are on your list?

Ian

Clinical Development

A Phase II clinical trial is underway in MS patients with data expected in the second half of calendar 2006. A Phase I clinical trial has demonstrated that EMZ701 is well-tolerated and has a good safety profile.

Creating Best-In-Class Multiple Sclerosis Product

Transition is developing MS-I.E.T. (a ...
Read more : Transition Therapeutics | Views : 1586 | Replies : 1




Intrathecal Methotrexate

Is anyone else on this treatment? I have received two infusions so far with no adverse effects. My neurologist STRONGLY recommended that I start this unapproved treatment. I did really well on Mito, but I have reached the maximum number of doses - and my MRI is a mess again. He feels these treatments will keep my disease in check until tyserbi reaches the market. I still feel like a guinea pig, starting a new ...
Read more : Intrathecal Methotrexate | Views : 2603 | Replies : 5


CombiRX

A trial combining treatments. Not really exciting but may prove useful.


Two MS drugs better than one?
Mon 17 Apr 2006 12:01 PM CST
WASHINGTON DC (myDNA News)

Enrollment has begun for CombiRx, a clinical trial that will examine the effectiveness of two medications taken in combination to treat relapsing-remitting multiple sclerosis (MS). The U.S. Food and Drug Administration (FDA) has already approved both drugs.

Sponsored by the Bethesda, Md.-based National Institutes of Health, the ...
Read more : CombiRX | Views : 1581 | Replies : 0


Tovaxin

PharmaFrontiers Corp, a company involved in the development and commercialization of cell therapies, announced today that the Company will make a poster presentation at the 2006 Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS) at the San Francisco Marriott on June 3, 2006.
The presentation will cover laboratory and clinical data from the Company's proprietary T-cell vaccination technology for the treatment of the autoimmune disease, multiple sclerosis and is entitled:

"Characterization and Clinical ...
Read more : Tovaxin | Views : 1631 | Replies : 0


MCT-125

Trial drug for treatment of fatigue in MS. Don't know what their other MS drugs are or what phase they are in.

MultiCell to Present Company's Portfolio of Novel Drug Candidates at BIO 2006 Conference; Company President Dr. Stephen Chang to Discuss Novel Therapeutic Candidates Targeting Multiple Sclerosis, Diabetes and Other Medical Needs

SAN DIEGO--(BUSINESS WIRE)--April 10, 2006 - MultiCell Technologies, Inc. (OTCBB:MCET), developer of therapeutics for the treatment of degenerative neurological diseases, metabolic and ...
Read more : MCT-125 | Views : 1398 | Replies : 0


NeuroVax

News about NeuroVax at the AAN. Sounds promising but I didn't read anything about disability progression.

The Immune Response Corporation's NeuroVax Restores FOXP3+ T-Cell Levels Believed to Help in Multiple Sclerosis
Oral Presentation at American Academy of Neurology

CARLSBAD, C.A. -- April 10, 2006 -- The Immune Response Corporation (OTCBB:IMNR.OB) announced that its T-cell receptor peptide vaccine candidate, NeuroVax™, induces increased FOXP3 expression resulting in re-establishment of normal levels of the FOXP3+ regulatory T-cells believed ...
Read more : NeuroVax | Views : 2058 | Replies : 0


Extension study FTY720 results

Phase II Data For FTY720 Shows Sustained Efficacy And Good Tolerability Over 18 Months In Patients With Relapsing Multiple Sclerosis (MS)

Data from the extension of a Phase II study to 18 months support the significant effects of FTY720 (fingolimod), a novel once-daily oral compound in development for treatment of relapsing-remitting multiple sclerosis (MS). More than two million people worldwide are estimated to suffer from MS, which is the leading cause of neurological disability in ...
Read more : Extension study FTY720 results | Views : 1915 | Replies : 0


High dose cyclophosphamide

Not a nice therapy, but looks like it helps if used early and agressively. On a side note, it's kind of sad that they are still discovering new stuff about this drug. It's been used at least experimentally in MS since the late 60's I believe. Better late than never?



High Dose Cyclophosphamide Achieves Rapid Clinical Improvements in Early, Aggressive Multiple Sclerosis: Presented at AAN

April 6, 2006 -- Preliminary data from a study utilizing ...
Read more : High dose cyclophosphamide | Views : 1562 | Replies : 0


 

Login  •  Register


Statistics

Total posts 232960 • Total topics 24949 • Total members 16087


Contact us | Terms of Service